Precisely targeting the interface between
innate and adaptive immunity.

Managing Partner Dr. Michael Ross joined SVLS as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco. Michael serves on the boards of Adimab, Alinea, Archemix, Intransasal, Itero Biopharmaceuticals, Link Medicine, Mpex, NKT Therapeutics, Sutro Pharmaceuticals and the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Aderis Pharmaceuticals, Arris Pharmaceutical, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, MetaXen, Rinat and Xenova.

Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin (human insulin-Lilly), Roferon (Interferon alpha -Roche), Protropin (hGH), Vice President of Development during the development of Activase, Nutropin and Pulmozyme. Michael then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, (now part of Celera), MetaXen, (now part of Exelixis), ExSAR and CyThera (now part of Novocell). Michael was most recently Managing Partner in Didyma, LLC, a biotechnology management consulting firm.

Michael received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.